Browsing by Author "Salido Galeote, Marta"

Sort by: Order: Results:

  • Assessment of a new ROS1 immunohistochemistry clone (SP384) for the identification of ROS1 rearrangements in patients with non-small cell lung carcinoma: the ROSING study
    Conde, Esther; Pijuan Andujar, Lara; Salido Galeote, Marta; Arriola Aperribay, Edurne; Company, Amparo; Lopez-Rios, Fernando (Elsevier, 2019)
    Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing ...
  • Clinical interest of LMO2 testing for the diagnosis of aggressive large B-Cell lymphomas
    Vazquez de las Heras, Ivonne; Papaleo, Natalia; García, Eugenia; Salido Galeote, Marta; Salar Silvestre, Antonio; Hernández Llodrà, Sílvia; Calvo Gonzalo, Xavier; Colomo Saperas, Luis Alberto (MDPI, 2020)
    MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability ...
  • Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
    Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • First description of the t(3;17) (q27;q21)/IGF2BP2::LSM12 translocation in marginal zone lymphoma
    Díez-Feijóo, Ramón; Fernández Rodríguez, M. Concepción; Lafuente, Marta; García Gisbert, Nieves, 1994-; Ferrer Del Alamo, Ana; Colomo Saperas, Luis Alberto; Salido Galeote, Marta; Salar Silvestre, Antonio (American Society of Hematology, 2023)
  • Guidelines for cytogenetic investigations in tumours.
    Hastings, Rosalind J.; Bown, Nick; Tibiletti, Maria G.; Debiec-Rychter, Maria; Vanni, Roberta; Espinet Solà, Blanca; van Roy, Nadine; Roberts, Paul; van den Berg-de-Ruiter, Eva; Bernheim, Alain; Schoumans, Jacqueline; Chatters, Steve; Zemanova, Zuzana; Stevens-Kroef, Marian; Simons, Annet; Heim, Sverre; Salido Galeote, Marta; Ylstra, Bauke; Betts, David R. (Nature publishing group, 2016)
  • MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
    Casadevall Aguilar, David; Gimeno Beltran, Javier; Clavé Safont, Sergi; Taus García, Álvaro; Pijuan Andujar, Lara; Arumí de Dios, Miriam; Lorenzo Perez, Marta; Menendez Romero, Silvia; Cañadas Castillo, Israel, 1984-; Albanell Mestres, Joan; Serrano Figueras, Sergi; Espinet Solà, Blanca; Salido Galeote, Marta; Arriola Aperribay, Edurne (Impact Journals, 2015)
    OBJECTIVE: We aimed to assess MET intratumoral heterogeneity and its potential impact on biomarker-based patient selection as well as potential surrogate biomarkers of MET activation. METHODS: Our study included 120 patients ...
  • Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA
    García Gisbert, Nieves, 1994-; Garcia-Ávila, Sara; Merchán, Brayan; Salido Galeote, Marta; Fernández Rodríguez, M. Concepción; Gibert Fernandez, Joan 1988-; Fernández-Ibarrondo, Lierni; Camacho Díaz, Laura; Lafuente, Marta; Longarón Rozalen, Raquel; Espinet Solà, Blanca; Vélez, Patricia; Pujol Vallverdú, Ramon Maria; Andrade-Campos, Marcio; Arenillas Rocha, Leonor; Salar Silvestre, Antonio; Calvo Gonzalo, Xavier; Besses Raebel, Carles; Bellosillo Paricio, Beatriz (American Society of Hematology, 2022)
    Molecular and cytogenetic studies are essential for diagnosis and prognosis in patients with myelodysplastic syndromes (MDSs). Cell-free DNA (cfDNA) analysis has been reported to be a reliable noninvasive approach for ...
  • Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
    Conde, Esther; Rojo, Federico; Gómez, Javier; Enguita, Ana Belen; Abdulkader, Ihab; González, Ana; Lozano, Dolores; Mancheño, Nuria; Salas, Clara; Salido Galeote, Marta; Salido, Eduardo; Álava, Enrique de (BMJ Publishing Group, 2022)
    The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses ...
  • Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features
    Calvo Gonzalo, Xavier; García-Gisbert, Nieves; Parraga, Ivonne; Gibert, Joan; Florensa Brichs, Lourdes; Andrade-Campos, Marcio; Merchan, Brayan; García-Avila, Sara; Montesdeoca, Sara; Fernández-Rodríguez, C.; Salido Galeote, Marta; Puiggros Metje, Anna Maria; Espinet Solà, Blanca; Colomo Saperas, Luis Alberto; Roman-Bravo, David; Bellosillo Paricio, Beatriz; Ferrer Del Alamo, Ana; Arenillas Rocha, Leonor (American Society of Hematology, 2020)
    Oligomonocytic chronic myelomonocytic leukemia (OM-CMML) is defined as those myelodysplastic syndromes (MDSs) or myelodysplastic/myeloproliferative neoplasms, unclassifiable with relative monocytosis (≥10% monocytes) and ...
  • Optical genome mapping: a promising new tool to assess genomic complexity in chronic lymphocytic leukemia (CLL)
    Puiggros Metje, Anna Maria; Ramos Campoy, Silvia; Kamaso Navarro, Joanna; de la Rosa, Mireia; Salido Galeote, Marta; Melero Vilella, Maria Carme; Rodríguez-Rivera, María; Gimeno Vázquez, Eva; Calvo, Xavier; Arenillas Rocha, Leonor; Ferrer Del Alamo, Ana; Espinet Solà, Blanca (MDPI, 2022)
    Novel treatments in chronic lymphocytic leukemia (CLL) have generated interest regarding the clinical impact of genomic complexity, currently assessed by chromosome banding analysis (CBA) and chromosomal microarray analysis ...
  • Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
    Calvo González, Xavier; Roman-Bravo, David; García Gisbert, Nieves, 1994-; Rodriguez-Sevilla, Juan José; García-Avila, Sara; Florensa Brichs, Lourdes; Gibert Fernandez, Joan 1988-; Fernández Rodríguez, M. Concepción; Salido Galeote, Marta; Puiggros Metje, Anna Maria; Espinet Solà, Blanca; Colomo Saperas, Luis Alberto; Bellosillo Paricio, Beatriz; Ferrer, Ana; Arenillas Rocha, Leonor (American Society of Hematology, 2022)
    atients with oligomonocytic chronic myelomonocytic leukemia (OM-CMML) are currently classified according to the 2017 World Health Organization myelodysplastic syndromes classification. However, recent data support considering ...
  • p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
    Solé, Laura; Lobo-Jarne, Teresa; Álvarez-Villanueva, Daniel; Alonso-Marañón, Josune; Guillén, Yolanda; Guix Arnau, Marta, 1974-; Sangrador, Irene; Rozalén, Catalina; Vert, Anna; Lop Gros, Joan; Salido Galeote, Marta; Bellosillo Paricio, Beatriz; García-Romero, Raquel; Garrido, Marta; González, Jessica; López Arribillaga, Erika, 1986-; Iglesias Coma, Mar; Celià-Terrassa, Toni; Bigas Salvans, Anna; Espinosa Blay, Lluís (Nature Research, 2022)
    Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and ...
  • Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
    Puiggros Metje, Anna Maria; Salido Galeote, Marta; Ferrer Del Alamo, Ana; Gimeno Vázquez, Eva; Abella Monreal, Eugenia; Espinet Solà, Blanca (Impact Journals, 2017)
    Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex ...
  • ROS1 copy number alterations are frequent in non-small cell lung cancer
    Clavé Safont, Sergi; Gimeno Beltran, Javier; Muñoz-Mármol, Ana M.; Vidal Barrull, Joana; Reguart, Noemí; Carcereny, Enric; Pijuan Andujar, Lara; Menendez Romero, Silvia; Taus García, Álvaro; Mate, José Luís; Serrano Figueras, Sergi; Albanell Mestres, Joan; Espinet Solà, Blanca; Arriola Aperribay, Edurne; Salido Galeote, Marta (Impact Journals, 2014)
    OBJECTIVES: We aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the correlation between FISH and IHC assays, and to investigate clinical implications of ROS1 copy number alterations (CNAs). ...
  • SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence
    Hernández Llodrà, Sílvia; Segalés Tañà, Laura, 1994-; Juanpere, Nuria; Lorenzo, Marta; Salido Galeote, Marta; Nonell Mazelón, Lara; López, David; Rodríguez-Vida, Alejo; Bellmunt Molins, Joaquim, 1959-; Fumadó Ciutat, Lluis; Cecchini Rosell, Lluís; Lloreta Trull, Josep, 1958- (Wiley, 2021)
    Background: In the non-ETS fusion of prostate cancer (PCa) pathway, SPOP mutations emerge as a distinct oncogenic driver subclass. Both SPOP downregulation and mutation can lead to SPOP target stabilization promoting ...